Scarica l'app Stockscreener
29.18
15.89%
4.00
Dopo l'orario di chiusura:
29.21
0.03
+0.10%
Precedente Chiudi:
$25.18
Aprire:
$32.31
Volume 24 ore:
8.89M
Relative Volume:
4.17
Capitalizzazione di mercato:
$2.17B
Reddito:
$97.36M
Utile/perdita netta:
$-172.42M
Rapporto P/E:
-12.70
EPS:
-2.2984
Flusso di cassa netto:
$-188.84M
1 W Prestazione:
+25.83%
1M Prestazione:
+22.61%
6M Prestazione:
+124.81%
1 anno Prestazione:
+120.89%
Intervallo 1D:
$28.84
$33.60
Intervallo di 1 settimana:
$24.42
$33.60
Portata 52W:
$10.38
$33.60
Xencor Inc Stock (XNCR) Company Profile
Nome
Xencor Inc
Settore
Industria
Telefono
626-305-5900
Indirizzo
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
29.18 | 2.17B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
517.49 | 131.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.67 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.85 | 79.39B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
869.33 | 54.67B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.87 | 41.95B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-30 | Ripresa | Wells Fargo | Overweight |
| 2026-03-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-29 | Aggiornamento | Barclays | Underweight → Overweight |
| 2025-09-17 | Ripresa | Barclays | Underweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2024-12-12 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Reiterato | BTIG Research | Buy |
| 2024-02-28 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Iniziato | BofA Securities | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-10-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-21 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-02-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2020-02-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-01-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-08-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-04-12 | Iniziato | Guggenheim | Buy |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2017-03-02 | Iniziato | Instinet | Neutral |
| 2017-03-02 | Reiterato | Wedbush | Outperform |
| 2016-10-04 | Iniziato | Piper Jaffray | Overweight |
| 2015-12-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-05 | Reiterato | MLV & Co | Buy |
| 2015-02-12 | Reiterato | Oppenheimer | Outperform |
| 2015-01-28 | Reiterato | MLV & Co | Buy |
| 2014-07-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Xencor Inc Borsa (XNCR) Ultime notizie
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor, Inc. (XNCR)What Are Researchers Saying About This Stock? - MarketBeat
Xencor to Host Webcast to Discuss Results Fro - Moomoo
Xencor schedules XmAb819 webcast: Wells Fargo targets Xencor stock at USD 30 - ad-hoc-news.de
symbol__ Stock Quote Price and Forecast - CNN
Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update? - Yahoo Finance
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - BioSpace
Xencor to present phase 1 data for kidney cancer treatment - Investing.com
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance Australia
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
RBC keeps USD 20 target for Xencor stock ahead of ESMO data - ad-hoc-news.de
Truist raises target for Xencor stock to USD 29 - ad-hoc-news.de
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Understanding Momentum Shifts in (XNCR) - Stock Traders Daily
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance UK
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor Q3 2026 Earnings Date and Estimates - MarketBeat
Xencor Stock: Better Funding For Obexelimab (NASDAQ:XNCR) - Seeking Alpha
Xencor stock fell 4.96 percent as targets diverged - AD HOC NEWS
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance UK
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Wells Fargo & Company Initiates Coverage on Xencor (NASDAQ:XNCR) - MarketBeat
Xencor stock falls 3.52 percent as Truist lifts its target - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Climb 4.6%Should You Buy? - MarketBeat
Xencor (NASDAQ:XNCR) Earns Buy Rating from Truist Financial - MarketBeat
Truist raises Xencor stock price target to $29 on drug trial outlook - Investing.com Nigeria
Truist Securities reiterates Buy rating on Xencor, $29 price target - TradingView
Truist raises Xencor stock price target to $29 on drug trial outlook - Investing.com
Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance Singapore
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating - Yahoo Finance
Xencor (XNCR) Holds Near $23.84 as Shares Consolidate Between Key LevelsATR Stop - careplusvn.com
Hsbc Holdings PLC Has $2.08 Million Position in Xencor, Inc. $XNCR - MarketBeat
Barclays Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $35 - moomoo.com
Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift - investing.com
Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift - Investing.com Canada
Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift - Investing.com UK
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 260,752 Shares of Xencor, Inc. $XNCR - MarketBeat
The Manufacturers Life Insurance Company Buys Shares of 49,696 Xencor, Inc. $XNCR - MarketBeat
XNCR stock holds steady as Xencor eyes next trial milestones - ad-hoc-news.de
Seven Fleet Capital Management LP Has $5.93 Million Stake in Xencor, Inc. $XNCR - MarketBeat
Man Group plc Takes Position in Xencor, Inc. $XNCR - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR - MarketBeat
XNCR Maintained by JP Morgan -- Price Target Raised to $21.00 - GuruFocus
Xencor Inc Azioni (XNCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xencor Inc Azioni (XNCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Feigal Ellen | Director |
Jun 18 '26 |
Proposed Sale |
13.06 |
6,843 |
89,370 |
0 |
| GORMAN KEVIN CHARLES | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
7,527 |
92,657 |
0 |
| GUSTAFSON KURT A | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,474 |
67,385 |
0 |
| RANIERI RICHARD J | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,474 |
67,385 |
0 |
| Montgomery Alan Bruce | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,064 |
62,338 |
0 |
| Montgomery Alan Bruce | Director |
Jun 15 '26 |
Sale |
12.31 |
5,064 |
62,338 |
15,547 |
| RANIERI RICHARD J | Director |
Jun 15 '26 |
Sale |
12.31 |
5,474 |
67,385 |
13,709 |
| GORMAN KEVIN CHARLES | Director |
Jun 15 '26 |
Sale |
12.31 |
7,527 |
92,657 |
11,378 |
| GUSTAFSON KURT A | Director |
Jun 15 '26 |
Sale |
12.31 |
5,474 |
67,385 |
14,709 |
| Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO |
Apr 10 '26 |
Sale |
12.29 |
3,499 |
42,990 |
75,898 |
2.42%
4.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):